FDA Hearing To Consider Incentives For Antimicrobial Drug Development
This article was originally published in The Pink Sheet Daily
Executive Summary
Tax incentives for R&D, plus strategies to cap the rise of antimicrobial resistance on the table.
You may also be interested in...
Advanced Life Sciences’ Cethromycin For CAP Cleared For FDA Submission
Firm plans third quarter NDA for mild-to-moderate community-acquired pneumonia indication.
FDA Stalls J&J’s Doribax For Hospital-Acquired Pneumonia
Agency needs three more months, company says.
Screening Hospital Patients For Drug-Resistant Infection Would Cut Costs – Industry Report
Data support reforms to Medicare in vitro diagnostics reimbursement policies, test makers say.